Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
McKinsey
Colorcon
Johnson and Johnson
Dow

Last Updated: September 25, 2022

PRISTIQ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Pristiq patents expire, and when can generic versions of Pristiq launch?

Pristiq is a drug marketed by Pf Prism Cv and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has sixty-eight patent family members in thirty-two countries.

The generic ingredient in PRISTIQ is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Pristiq

A generic version of PRISTIQ was approved as desvenlafaxine succinate by ALEMBIC PHARMS LTD on June 29th, 2015.

  Try it Free

Drug patent expirations by year for PRISTIQ
Drug Prices for PRISTIQ

See drug prices for PRISTIQ

Drug Sales Revenue Trends for PRISTIQ

See drug sales revenues for PRISTIQ

Recent Clinical Trials for PRISTIQ

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
David SteffensPhase 4
National Institute of Mental Health (NIMH)Phase 4
Seoul National University Bundang HospitalPhase 4

See all PRISTIQ clinical trials

Paragraph IV (Patent) Challenges for PRISTIQ
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
PRISTIQ Extended-release Tablets desvenlafaxine succinate 25 mg 021992 1 2015-05-08
PRISTIQ Extended-release Tablets desvenlafaxine succinate 50 mg and 100 mg 021992 12 2012-02-29

US Patents and Regulatory Information for PRISTIQ

PRISTIQ is protected by three US patents.

Patents protecting PRISTIQ

Succinate salt of O-desmethyl-venlafaxine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION

Succinate salt of O-desmethyl-venlafaxine
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Derivatives of venlafaxine and methods of preparing and using the same
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 AB RX Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PRISTIQ

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-002 Feb 29, 2008 See Plans and Pricing See Plans and Pricing
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-003 Aug 20, 2014 See Plans and Pricing See Plans and Pricing
Pf Prism Cv PRISTIQ desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 021992-001 Feb 29, 2008 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Colorcon
Moodys
McKinsey
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.